Michelle is an experienced, USPTO-registered patent practitioner who understands the necessary role of active intellectual property management to the business success of all biotechnology and medical device companies – from start-ups to large biopharma organizations.
Her in-house experiences range from being a member of the legal departments at Genentech and Bristol Myers Squibb to IP and transactional work supporting the successful “exits” of ZymoGenetics (bought by BMS), Molecular Templates (now on NASDAQ), and Capsugel (bought by Lonza). This wide range of experience forms the basis for her strategic, actionable, and business savvy approaches to patent, trademark, trade secret, and copyright issues, whatever the size of company involved. A true client’s advocate, she works to forward the business goals of her clients while remaining within the budget available.
Michelle has worked on a wide variety of biotechnology subject matter over her career, including medical devices, large and small molecule therapeutics, gene therapies, stem cell therapies, diagnostic testing, and next generation sequencing methods. Her therapeutic areas of expertise include oncology, immunology, neurological disease, and metabolic disease.
Michelle earned her JD from Rutgers-Newark School of Law (high honors) where she was a member of the Law Review. Prior to going to law school she worked as a patent agent and was a patent examiner at the USPTO. She received her Master’s degree in Genetics from Columbia University and her Bachelor’s degree in Biology from Duke University.